Mesoblast IND Clearance to Directly Proceed to Registrational Trial for OK of Ryoncil® in Duchenne

Mesoblast (Nasdaq: MESO) announced FDA IND clearance to proceed directly to a registrational trial of Ryoncil® in Duchenne muscular dystrophy (DMD) on April 7, 2026. The randomized trial will enroll 76 patients aged 5–9, dosing 7 infusions of 2 x 106 cells/kg over 9 months, with time-to-stand at nine months as the primary endpoint. Mesoblast cites Ryoncil’s approved pediatric safety profile in steroid-refractory aGvHD, preclinical DMD efficacy, an FDA-approved manufacturing process, and a collaboration with Parent Project Muscular Dystrophy to support enrollment.

https://www.stocktitan.net/news/MESO/mesoblast-receives-ind-clearance-from-fda-to-directly-proceed-to-n7yv066qzrel.html